High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide. Issue 1 (December 2016)

• Record Type: Journal Article
• Authors: Pourabdollah, Maryam; Bahmanyar, Mohammad; Atenafu, Eshetu; Reece, Donna; Hou, Jian; Chang, Hong
• Is Part Of: Journal of hematology & oncology. Volume 9:Issue 1(2016)
• Page Start: 1
• Page End: 4
• Publication Date: 2016-12
• Subjects: Hematology -- Periodicals; Oncology -- Periodicals; Blood -- Diseases -- Periodicals; 616.994
• DOI: 10.1186/s13045-016-0354-2
• Languages: English
• ISSNs: 1756-8722

Abstract

Abstract The aim of this study is to assess nucleoprotein expression of IKZF1/3 in patients with relapsed/refractory multiple myeloma (MM) who received lenalidomide-based therapy and correlated them with their clinical outcomes. A total of 50 patients diagnosed with MM were entered in the study with the median follow-up of 86.4 months. By immunohistochemistry (IHC), IKZF1 and IKZF3 were expressed in 72 and 58% of the cases, respectively. IKZF1 and IKZF3 expressions were associated with longer median progression free survival (P = 0.0029 andP < 0.0001) and overall survival (P = 0.0014 andP < 0.0001). IKZF3 expression also appears predicted a favorable response to the lenalidomide-based therapy.